

Tarec Christoffer El-Galaly

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4505314/tarec-christoffer-el-galaly-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

1,529
citations

23
h-index

36
g-index

136
ext. papers

2,026
ext. citations

3.9
avg, IF

4.23
L-index

#	Paper	IF	Citations
122	Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark.. <i>Blood Cancer Journal</i> , 2022 , 12, 16	7	0
121	TRAIL Score: A Simple Model to Predict Immunochemotherapy Tolerability in Patients With Diffuse Large B-Cell Lymphoma.. <i>JCO Clinical Cancer Informatics</i> , 2022 , 6, e2100121	5.2	0
120	Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT.. <i>Bone Marrow Transplantation</i> , 2022 ,	4.4	0
119	Timing of high dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1,384 patients.. <i>Blood</i> , 2022 ,	2.2	3
118	Psychotropic Drug Use in Acute Myeloid Leukaemia (AML) and Myelodysplastic Syndrome (MDS): A Danish Nationwide Matched Cohort Study of 2404 AML and 1307 MDS Patients.. <i>Clinical Epidemiology</i> , 2022 , 14, 225-237	5.9	
117	Cardiovascular diseases in elderly survivors of diffuse large B-cell lymphoma: a Danish population-based cohort study.. <i>Leukemia and Lymphoma</i> , 2022 , 1-10	1.9	
116	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.. <i>Lancet Haematology</i> , 2022 , 9, e374-e384	14.6	0
115	Patient-reported outcomes in patients with hematological relapse or progressive disease: a longitudinal observational study. <i>Health and Quality of Life Outcomes</i> , 2021 , 19, 251	3	1
114	Risk of Incident Diabetes and Dysregulated Pre-Existing Diabetes Mellitus in Newly Diagnosed Lymphoma Patients Treated with Steroid-Containing Immunochemotherapy: A Danish Population-Based Study. <i>Blood</i> , 2021 , 138, 454-454	2.2	
113	High-Dose Methotrexate Is Not Associated with Reduction in CNS Relapse in Patients with Aggressive B-Cell Lymphoma: An International Retrospective Study of 2300 High-Risk Patients. <i>Blood</i> , 2021 , 138, 181-181	2.2	3
112	Sex Differences in Lymphoma Incidence and Excess Mortality By Subtype: A Comprehensive National Study. <i>Blood</i> , 2021 , 138, 2534-2534	2.2	
111	The Impact of Trial Eligibility Criteria on Outcomes in a Nationwide Cohort of Newly Diagnosed DLBCL Patients Treated with R-CHOP. <i>Blood</i> , 2021 , 138, 53-53	2.2	0
110	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021 , 138, 3527-3527	2.2	0
109	A Randomized Placebo-Controlled Trial of Primary Prophylaxis with Weekly Alendronate Against Glucocorticoid-Induced Osteoporosis in Lymphoma Patients Treated with Steroid-Containing Chemotherapy.. <i>Blood</i> , 2021 , 138, 456-456	2.2	
108	Mental Health Among Patients with Non-Hodgkin Lymphoma: A Danish Nationwide Study of Psychotropic Drug Use in 7,201 Patients and 36,005 Matched Comparators. <i>Blood</i> , 2021 , 138, 51-51	2.2	
107	Level of Unique T-Cell Clonotypes Are Associated with Clonal Hematopoiesis and Survival in Patients with Lymphoma Intended for Autologous Stem Cell Transplant. <i>Blood</i> , 2021 , 138, 3942-3942	2.2	
106	Early Integration of High Dose Methotrexate to Frontline DLBCL Therapy Does Not Impact CNS Relapse Compared to End of Treatment Delivery: A Multicentre International Analysis of 1384 Patients. <i>Blood</i> , 2021 , 138, 452-452	2.2	

105	Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001-2016: a Danish nationwide cohort study. <i>Leukemia and Lymphoma</i> , 2021 , 62, 2014-2017	1.9	0
104	Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2021 , 96, 599-605	7.1	1
103	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1129-1138	2.2	7
102	Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review. <i>Blood Advances</i> , 2021 , 5, 2426-2437	7.8	4
101	Parenthood Rates and Use of Assisted Reproductive Techniques in Younger Hodgkin Lymphoma Survivors: A Danish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3463-3472	2.2	0
100	The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs. <i>BMC Cancer</i> , 2021 , 21, 829	4.8	
99	Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study. <i>British Journal of Haematology</i> , 2021 , 193, 482-487	4.5	1
98	Clinical characteristics and outcomes among 2347 patients aged 85 years with major lymphoma subtypes: a Nordic Lymphoma Group study. <i>British Journal of Haematology</i> , 2021 , 192, 551-559	4.5	4
97	Detecting deviations from the efficacy and safety results of single-arm trials using real-world data: The case of a CAR-T cell therapy in B-cell lymphoma. <i>Pharmacoepidemiology and Drug Safety</i> , 2021 , 30, 514-519	2.6	1
96	Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system. <i>Future Oncology</i> , 2021 , 17, 3331-3341	3.6	
95	Hematological cancer survivors' experiences of participating in a shared care follow-up-an exploratory interview study. <i>Journal of Cancer Survivorship</i> , 2021 , 15, 620-629	5.1	
94	Risk for Myocardial Infarction Following 5-Fluorouracil Treatment in Patients With Gastrointestinal Cancer: A Nationwide Registry-Based Study. <i>JACC: CardioOncology</i> , 2021 , 3, 725-733	3.8	0
93	Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. <i>Leukemia</i> , 2020 , 34, 3256-3268	10.7	17
92	Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas. <i>Acta Oncologica</i> , 2020 , 59, 766-774	3.2	2
91	On estimating the time to statistical cure. <i>BMC Medical Research Methodology</i> , 2020 , 20, 71	4.7	4
90	Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1345-1354	1.9	6
89	Mantle Cell Lymphoma of Mucosa-Associated Lymphoid Tissue: A European Mantle Cell Lymphoma Network Study. <i>HemaSphere</i> , 2020 , 4, e302	0.3	5
88	Mantle cell lymphoma - where precision medicine based on response-adapted treatment strategies could show its full worth. <i>British Journal of Haematology</i> , 2020 , 189, 600-602	4.5	

87	Development of a Precision Medicine Workflow in Hematological Cancers, Aalborg University Hospital, Denmark. <i>Cancers</i> , 2020 , 12,	6.6	6
86	Normal myeloid progenitor cell subset-associated gene signatures for acute myeloid leukaemia subtyping with prognostic impact. <i>PLoS ONE</i> , 2020 , 15, e0229593	3.7	2
85	The Burkitt Lymphoma International Prognostic Index (BL-IPI). <i>Blood</i> , 2020 , 136, 46-49	2.2	
84	Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. <i>British Journal of Haematology</i> , 2020 , 189, 661-671	4.5	8
83	Shared care follow-up of patients with B-cell neoplasms based on nurse-led telephone consultations and PRO-data: a feasibility study from the North Denmark Region. <i>BMC Health Services Research</i> , 2020 , 20, 1047	2.9	
82	Implementing the FAIR Data Principles in precision oncology: review of supporting initiatives. <i>Briefings in Bioinformatics</i> , 2020 , 21, 936-945	13.4	12
81	Depression and anxiety in Hodgkin lymphoma patients: A Danish nationwide cohort study of 945 patients. <i>Cancer Medicine</i> , 2020 , 9, 4395-4404	4.8	7
80	Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma. <i>Expert Review of Hematology</i> , 2020 , 13, 655-668	2.8	3
79	The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study. <i>British Journal of Haematology</i> , 2020 , 190, 236-243	4.5	6
78	A comparative study of standardized quantitative and visual assessment for predicting tumor volume and outcome in newly diagnosed diffuse large B-cell lymphoma staged with 18F-FDG PET/CT. <i>EJNMMI Research</i> , 2019 , 9, 36	3.6	4
77	Real world data as a key element in precision medicine for lymphoid malignancies: potentials and pitfalls. <i>British Journal of Haematology</i> , 2019 , 186, 409-419	4.5	3
76	No differential overall or relative survival effect of rituximab in male and female patients with diffuse large B-cell lymphoma: a Danish population-based study of 3783 patients. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2798-2801	1.9	
75	Estimating the loss of lifetime function using flexible parametric relative survival models. <i>BMC Medical Research Methodology</i> , 2019 , 19, 23	4.7	4
74	Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 522-529	4	12
73	Risk of death, relapse or progression, and loss of life expectancy at different progression-free survival milestones in primary central nervous system lymphoma. <i>Leukemia and Lymphoma</i> , 2019 , 60, 2516-2523	1.9	6
72	Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 703-713	2.2	12
71	Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases. <i>Pharmaceutical Medicine</i> , 2019 , 33, 83-88	2.3	2
70	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. <i>Blood Advances</i> , 2019 , 3, 2013-2021	7.8	19

69	Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1580-1583	1.9	3
68	Definitive radiotherapy for localized follicular lymphoma staged by F-FDG PET-CT: a collaborative study by ILROG. <i>Blood</i> , 2019 , 133, 237-245	2.2	57
67	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018 , 93, 57-68	7.5	37
66	Evolution of relative survival for acute promyelocytic leukemia patients alive at landmark time-points: a population-based study. <i>Leukemia</i> , 2018 , 32, 2263-2303	10.7	2
65	Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma. <i>British Journal of Haematology</i> , 2018 , 182, 297-301	4.5	5
64	PET/CT for Staging; Past, Present, and Future. <i>Seminars in Nuclear Medicine</i> , 2018 , 48, 4-16	5.4	31
63	Questioning the value of routine imaging for patients with mantle cell lymphoma in first remission. <i>Leukemia and Lymphoma</i> , 2018 , 59, 775-777	1.9	
62	Predictive Value of PET Response Combined with Baseline Metabolic Tumor Volume in Peripheral T-Cell Lymphoma Patients. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 589-595	8.9	31
61	FDG-PET/CT in the management of lymphomas: current status and future directions. <i>Journal of Internal Medicine</i> , 2018 , 284, 358-376	10.8	29
60	Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study. <i>European Journal of Cancer</i> , 2018 , 99, 86-96	7.5	42
59	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology,the</i> , 2018 , 5, e563-e598	14.6	62
58	Relapse Risk and Loss in Expectation of Lifetime in Young Classical Hodgkin Lymphoma Patients - a Nordic Lymphoma Group Study of 2,582 Patients. <i>Blood</i> , 2018 , 132, 930-930	2.2	0
57	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. <i>PLoS ONE</i> , 2018 , 13, e0193249	3.7	5
56	Risk of Death, Relapse or Progression, and Loss of Life Expectancy at Different Progression-Free Survival Milestones in Primary Central Nervous System Lymphoma. <i>Blood</i> , 2018 , 132, 1699-1699	2.2	
55	Clinical Impact of Clonal Hematopoiesis after Autologous Stem Cell Transplantation for Lymphoma: A National Population-Based Cohort Study. <i>Blood</i> , 2018 , 132, 607-607	2.2	1
54	Normalization of Survival and No Relapses after One Year in Adult Burkitt Lymphoma Patients Treated with Intensive Immunochemotherapy: An International Study of 159 Real-World Patients. <i>Blood</i> , 2018 , 132, 452-452	2.2	
53	Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: a critical assessment of the R-IPI, IPI, and NCCN-IPI. <i>Cancer Medicine</i> , 2018 , 7, 114-122	4.8	19
52	Optimizing Outcome Prediction in Diffuse Large B-Cell Lymphoma by Use of Machine Learning and Nationwide Lymphoma Registries: A Nordic Lymphoma Group Study. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-13	5.2	18

51	Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines. <i>British Journal of Haematology</i> , 2018 , 183, 717-726	4.5	22
50	Limited value of routine follow-up visits in chronic lymphocytic leukemia managed initially by watch and wait: A North Denmark population-based study. <i>PLoS ONE</i> , 2018 , 13, e0208180	3.7	1
49	Minimal Loss of Lifetime for Patients With Diffuse Large B-Cell Lymphoma in Remission and Event Free 24 Months After Treatment: A Danish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 778-784	2.2	48
48	Molecular classification of tissue from a transformed non-HogkinB lymphoma case with unexpected long-time remission. <i>Experimental Hematology and Oncology</i> , 2017 , 6, 3	7.8	1
47	The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: An international multicenter study of 1532 patients treated with chemoimmunotherapy. <i>European Journal of Cancer</i> , 2017 , 75, 195-203	7.5	35
46	Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients. <i>European Journal of Haematology</i> , 2017 , 98, 355-362	3.8	2
45	Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2815-2823	1.9	10
44	R-CHOP(-like) treatment of diffuse large B-cell lymphoma significantly reduces CT-assessed vertebral bone density: a single center study of 111 patients. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1105-1113	1.9	16
43	Little value of surveillance magnetic resonance imaging for primary CNS lymphomas in first remission: results from a Danish Multicentre Study. <i>British Journal of Haematology</i> , 2017 , 176, 671-673	4.5	6
42	Reply to H.J adams et al: "Is FDG-PET/CT a sensitive and specific method for the detection of extranodal involvement in diffuse large B-cell lymphoma?". <i>American Journal of Hematology</i> , 2016 , 91, E2-3	7.1	
41	Characterization of memory B cells from thymus and its impact for DLBCL classification. <i>Experimental Hematology</i> , 2016 , 44, 982-990.e11	3.1	2
40	To maintain or not, that is the question. <i>British Journal of Haematology</i> , 2016 , 174, 321-2	4.5	
39	Blood on the tracks - toward precision medicine. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1753-4	1.9	
38	The application of human phase 0 microdosing trials: A systematic review and perspectives. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1281-90	1.9	7
37	An International Collaborative Study of Outcome and Prognostic Factors in Patients with Secondary CNS Involvement By Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016 , 128, 1874-1874	2.2	2
36	PET/CT for HL Staging 2016 , 1-13		
35	Normal B-Cell Gene Expression Signatures Classifies Chronic Lymphocytic Leukemia into Distinct Subtypes - Indication of Plasticity. <i>Blood</i> , 2016 , 128, 2017-2017	2.2	
34	miR-155 as a Biomarker in B-Cell Malignancies. <i>BioMed Research International</i> , 2016 , 2016, 9513037	3	38

33	The Danish National Lymphoma Registry: Coverage and Data Quality. <i>PLoS ONE</i> , 2016 , 11, e0157999	3.7	47
32	hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine. <i>PLoS ONE</i> , 2016 , 11, e0163711	3.7	7
31	No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study. <i>British Journal of Haematology</i> , 2016 , 173, 236-44	4.5	24
30	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016 , 91, 894-9	7.1	11
29	The myeloma stem cell concept, revisited: from phenomenology to operational terms. <i>Haematologica</i> , 2016 , 101, 1451-1459	6.6	35
28	Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. <i>British Journal of Haematology</i> , 2016 , 175, 876-883	4.5	18
27	Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies. <i>Cancer Treatment and Research</i> , 2015 , 165, 125-46	3.5	8
26	Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. <i>BMC Cancer</i> , 2015 , 15, 235	4.8	34
25	Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1379-88	2.2	73
24	Circulating tumor necrosis factor- β and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2476-8	1.9	6
23	A population-based study of prognosis in advanced stage follicular lymphoma managed by watch and wait. <i>British Journal of Haematology</i> , 2015 , 169, 435-44	4.5	24
22	Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. <i>American Journal of Hematology</i> , 2015 , 90, 1041-6	7.1	50
21	Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3993-8	2.2	62
20	Utility of interim and end-of-treatment PET/CT in peripheral T-cell lymphomas: A review of 124 patients. <i>American Journal of Hematology</i> , 2015 , 90, 975-80	7.1	40
19	The Absolute Number of Extranodal Sites Detected By PET-CT Is a Powerful Predictor of Secondary Central Nervous System Involvement in Patients with Diffuse Large B-Cell Lymphoma Treated with R-CHOP. <i>Blood</i> , 2015 , 126, 3905-3905	2.2	1
18	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. <i>Blood</i> , 2015 , 126, 3865-3865	2.2	
17	Subtyping of B-Cell Malignancies By B-Cell Subset Associated Gene Signatures (BAGS), Generated from Human Primary and Secondary Lymphoid Organs.. <i>Blood</i> , 2015 , 126, 5347-5347	2.2	
16	Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014 , 89, 575-80	7.1	40

15	Human B-cell cancer cell lines as a preclinical model for studies of drug effect in diffuse large B-cell lymphoma and multiple myeloma. <i>Experimental Hematology</i> , 2014 , 42, 927-38	3.1	13
14	Impact of 18F-fluorodeoxyglucose positron emission tomography/computed tomography staging in newly diagnosed classical Hodgkin lymphoma: fewer cases with stage I disease and more with skeletal involvement. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2349-55	1.9	20
13	Prognostic impact of clinician-based interpretation of 18F-fluorodeoxyglucose positron emission tomography/computed tomography reports obtained in patients with newly diagnosed diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1563-9	1.9	5
12	Role of Bone Marrow Biopsy in the Staging of Diffuse Large B-Cell Lymphoma in the PET/CT Era. <i>Blood</i> , 2014 , 124, 2960-2960	2.2	
11	A Diffuse Large B-Cell Lymphoma Classification System That Associates Normal B-Cell Subset Phenotypes with Prognosis. <i>Blood</i> , 2014 , 124, 2973-2973	2.2	
10	Prognostic Impact of Extranodal Diffuse Large B-Cell Lymphoma in the Era of Immunochemotherapy and PET/CT Staging. <i>Blood</i> , 2014 , 124, 1630-1630	2.2	1
9	Single nucleotide polymorphisms and the risk of venous thrombosis: results from a Danish case-cohort study. <i>British Journal of Haematology</i> , 2013 , 160, 838-41	4.5	16
8	The International Prognostic Index Predicts Outcome In Patients With Untreated Nodal Peripheral T-Cell Lymphomas Staged With PET/CT. <i>Blood</i> , 2013 , 122, 5077-5077	2.2	
7	Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4508-14	2.2	191
6	Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. <i>Haematologica</i> , 2012 , 97, 931-6	6.6	61
5	Prognostic Impact of Clinician-Based Interpretation of FDG-PET/CT Reports Obtained in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma.. <i>Blood</i> , 2012 , 120, 2646-2646	2.2	
4	Clinical Features and Outcome in Newly Diagnosed Hodgkin Lymphoma Patients Presenting with PET/CT-Ascertained Focal Skeletal Lesions.. <i>Blood</i> , 2012 , 120, 2637-2637	2.2	
3	Disease Extent in Newly Diagnosed Hodgkin Lymphoma: A Comparison of CT and PET/CT Staged Patients. <i>Blood</i> , 2012 , 120, 1532-1532	2.2	
2	Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center. <i>Leukemia and Lymphoma</i> , 2011 , 52, 597-603	1.9	42
1	Routine Bone Marrow Biopsy Adds Little Diagnostic Information in Patients with Newly Diagnosed Hodgkin Lymphoma Undergoing PET/CT Staging. <i>Blood</i> , 2011 , 118, 2627-2627	2.2	